Research Aprea Therapeutics' (Nasdaq:APRE) stock price, latest news & stock analysis. Find everything from its Valuation, Future Growth, Past Performance. Get Aprea Therapeutics Inc (ye-ti.ru) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments. Track Aprea Therapeutics Inc (APRE) Stock Price, Quote, latest community messages, chart, news and other stock related information. View today's Aprea Therapeutics Inc stock price and latest APRE news and analysis. Create real-time notifications to follow any changes in the live stock. Discover real-time Aprea Therapeutics, Inc. Common stock (APRE) stock prices, quotes, historical data, news, and Insights for informed trading and.
Where is Aprea Therapeutics' corporate headquarters? Aprea Therapeutics, Inc. Old Easton Road Doylestown, PA On Monday morning 08/26/ the Aprea Therapeutics Inc Registered Shs share started trading at the price of $ Compared to the closing price on Friday 08/. Aprea Therapeutics' stock opens % above IPO price, then rises further. Aprea Therapeutics Inc. got off to a positive start as a public company Thursday. Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing cancer therapeutics that reactivate mutant p Aprea Therapeutics (NASDAQ: APRE) announced FDA clearance for their new oral WEE1 inhibitor, APR, and plans to initiate Phase 1 clinical trials in June. Aprea Therapeutics Inc (NASDAQ: APRE) shares are trading lower by % to $ after the company announced pricing of a $ million underwritten public. Aprea Therapeutics focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the provision of cancer therapeutics. Aprea Therapeutics Inc Resistance and Support ; First Resistance, $ ; Second Resistance, $ ; Third Resistance, $ Previous close. The last closing price. $ ; Day range. The range between the high and low prices over the past day. $ - $ ; Year range. The range. On average, Wall Street analysts predict that Aprea Therapeutics's share price could reach $ by Aug 13, The average Aprea Therapeutics stock price.
Aprea Therapeutics, Inc. (APRE) ; Sep 4, , , , , ; Sep 3, , , , , Aprea Therapeutics Inc APRE:NASDAQ · Open · Day High · Day Low · Prev Close · 52 Week High · 52 Week High Date03/01/24 · 52 Week Low The average price target for Aprea Therapeutics Inc is $ This is based on 3 Wall Streets Analysts month price targets, issued in the past 3 months. Aprea Therapeutics (APRE) reported Q1 earnings per share (EPS) of -$, beating estimates of -$ by %. In the same quarter last year, Aprea. DOYLESTOWN, Pa., Aug. 28, (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea” or the “Company”), a clinical stage biopharmaceutical. Aprea Therapeutics Inc Resistance and Support ; First Resistance, $ ; Second Resistance, $ ; Third Resistance, $ Aprea Therapeutics Inc. ; Market Value, $M ; Shares Outstanding, M ; EPS (TTM), -$ ; P/E Ratio (TTM), N/A ; Dividend Yield, N/A. View Aprea Therapeutics, Inc. APRE stock quote prices, financial information, real-time forecasts, and company news from CNN. Data Provided by Refinitiv. Minimum 15 minutes delayed. Stock Information. Stock Quote & Chart · Historic Price Lookup.
Aprea Therapeutics, Inc. Stock ; Calendar. - H.C. Wainwright Global Investment Conference ; Mean consensus. BUY ; Number of Analysts. 3 ; Last Close. Weekly Stock Data ; August 26, , , ; August 27, , , ; August 28, , , ; August 29, , , Aprea Therapeutics Inc ; Dec, Downgrade, Robert W. Baird, Outperform → Neutral ; Dec, Initiated, Berenberg, Buy, $ Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer. As of Aug the stock price of Aprea Therapeutics is $ What is the current market cap of Aprea Therapeutics? The current market capitalization of.
Aprea Therapeutics Inc. (APRE) Share Price · $ As on Aug EDT · Stock Range · Aprea Therapeutics Inc. · Essential Checks · Is there a threat to the. Aprea's lead product candidate, APR, or eprenetapopt, is a small molecule p53 reactivator that is in clinical development for hematologic malignancies. Stock split history for Aprea Therapeutics. Aprea Therapeutics Inc. ; Open. ; High. ; 52wk High. ; Volume. 3, ; Beta. Aprea Therapeutics Inc. (APRE) Per-Share Earnings, Actuals and Estimates Quarterly Annual APRE will report Q2 earnings on 08/08/